known to occur in a variety of disorders, including dilated cardiomyopathy, valvular and congenital heart disease, and cardiac ion channelopathies such as the long QT syndrome.
In a minority of patients, VT occurs in the absence of structural heart disease. Despite the established mortality benefit of the implantable cardioverter defibrillator (ICD) in patients at risk of lethal arrhythmias, recurrent VT/VF events continue to be a source of morbidity and impaired quality of life in such patients. Antiarrhythmic therapy is indicated in select patients to treat symptomatic VT episodes, to are the leading cause of sudden cardiac death (SCD), which in turn represents about half of all cardiovascular mortality and accounts for over 350,000 deaths annually in the United States [1] . VT can be either sustained (lasting [30 s) or nonsustained, and can have a uniform QRS morphology (monomorphic) or a variable morphology (polymorphic). It is the most common wide complex tachycardia seen in association with structural heart disease [2] . The vast majority of VT is related to myocardial pathologic processes that promote cardiac fibrosis or inflammation, most commonly from coronary artery disease (CAD) in over 80% of patients [3] . However, myocarditis, dilated cardiomyopathy, congenital heart disease, cardiac infiltrative diseases, arrhythmogenic right ventricular cardiomyopathy, and hypertrophic cardiomyopathy are also known to contribute to an arrhythmogenic substrate. In about 10% of patients, VT occurs in the absence of structural heart disease [4] . This subset of VT is thought to be either idiopathic or related to primary electrical disease, such as the long QT syndrome, Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia (CPVT), or other cardiac ion channelopathies [5, 6] .
The principal mechanisms of arrhythmogenesis in the heart are abnormal automaticity, triggered activity from afterdepolarizations, and myocardial reentry [2] .
Triggered activity and abnormal automaticity are the most important mechanisms of focal VT arising from the ventricular outflow tracts, although microreentrant circuits may also play a role. In the setting of myocardial scar from CAD, macroreentry is the most common mechanism contributing to VT [7, 8] . It is estimated that 1-5% of all patients with a history of previous myocardial infarction (MI) will develop VT. In the setting of acute MI, on the other hand, the incidence of VT/VF ranges from 2% to 10% [9, 10] . This upfront arrhythmic risk has been reduced by early coronary reperfusion strategies, such as thrombolytics and primary angioplasty, in the acute phases of MI [2, 11] . The electrical substrate for VT following acute MI is established as early as 2 weeks postinfarction, based on programmed ventricular stimulation studies, and presumably is present indefinitely [12] . The abnormal substrate is characterized by inflammation and fibrosis, cardiac hypertrophy, abnormal cell coupling, and ion channel expression in the myocardium that promote ventricular arrhythmia [5] . The subsequent development of VT in at-risk patients results from the interplay of the abnormal myocardial substrate and arrhythmogenic triggers. The roles played by the autonomic nervous system, hemodynamic stress, metabolic abnormalities, and ventricular premature depolarizations as proarrhythmic triggers have all been well described [6, 13] . The only intervention demonstrated to improve survival in patients at risk of SCD from ventricular arrhythmias is the implantable cardioverter defibrillator (ICD). It is indicated for secondary prevention in patients with a history of sustained VT/VF, and for primary prevention in patients with a history of heart failure or previous MI and left ventricular ejection fraction (LVEF) of 35% or less [14] .
There are several limitations, however, with the ICD as primary therapy for VT/VF. First, and most important, is that although the ICD effectively terminates ventricular arrhythmias, it does not prevent them. Second is the morbidity associated with both appropriate and inappropriate ICD shocks. Third, the current selection criteria for ICD candidacy are imperfect, as many ICD recipients never receive appropriate ICD therapy for VT/VF, whereas many other patients with LVEF greater than 35% who are not eligible for the ICD go on to experience SCD [15] . In addition, the benefit of the ICD is not established in the early post-MI period; despite an increased risk of arrhythmic death in this population, there was no difference in total mortality in patients within 6 and 40 days of acute MI treated with the ICD vs. medical therapy in a randomized trial [16] .
Antiarrhythmic drug therapy is commonly used as adjunctive treatment in ICD recipients for the suppression of VT/VF episodes. In the Antiarrhythmic Versus Implantable Defibrillator (AVID) trial of secondary prevention ICD therapy, the 1-year arrhythmia event rate was 90% in the ICD arm, and was reduced to 64% with concurrent antiarrhythmic therapy [17] .
Overall, up to 70% of patients with an ICD receive adjuvant antiarrhythmic drug therapy, even though there is no medication formally approved for this indication [18] . The indications for adjunctive antiarrhythmic therapy are: to reduce the incidence of appropriate and inappropriate ICD shocks; to slow the rate of spontaneous VT episodes to improve their hemodynamic tolerance and to facilitate pace termination by the ICD; to treat symptomatic VT episodes; to improve quality of life; and potentially to reduce hospitalizations related to cardiac arrhythmia [18] .
Current antiarrhythmic therapy for VT is limited by its potential for both cardiac and extracardiac toxicity, including the risk of proarrhythmia, and by its limited efficacy. In the Optimal Pharmacological Therapy in Cardioverter Defibrillator Patients (OPTIC) trial, amiodarone and sotalol were each significantly more effective in preventing ICD shocks compared to beta-blockers alone, but 1-year shock rates were still 10% in the amiodarone arm and 24% in the sotalol arm, with drug-related adverse effects leading to discontinuation in one in five patients [19] . This review will summarize their findings and discuss more recent data on emerging pharmacotherapies for ventricular arrhythmia.
METHODS
The following review article incorporates data from clinical trials, review articles, and textbooks to provide a comprehensive and up- 
DISCUSSION

Current Antiarrhythmic Therapy
Classification of Antiarrhythmic Agents
The most common classification scheme for antiarrhythmic agents is the Vaughan Williams classification, which characterizes drugs based on their ability to block specific ion currents or cell receptors [20] . properties [38] .
Beta-Blockers
Beta-blockers are considered first-line therapy for patients with systolic heart failure and following acute MI for their established survival benefit in these populations [30, 31, 39, 40] . In addition, beta-blockers are indicated in the treatment of certain ion channelopathies, such as congenital long QT syndrome and CPVT [41] .
In the Cardiac Insufficiency Bisoprolol Study II (CIBIS-II), bisoprolol reduced all-cause mortality by 34% and sudden cardiac death by 44% in patients with heart failure [30] [34] .
Conversely, in the era of the primary prevention ICD, amiodarone did not confer a survival benefit over placebo in the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) of symptomatic heart failure patients with LVEF of 35% or less [45] . Amiodarone plus beta-blockers was shown to be superior to monotherapy with sotalol or beta-blockers in the OPTIC trial for the reduction of shocks in secondary prevention ICD recipients [19] . As a result of its greater efficacy, amiodarone is the most common antiarrhythmic agent used for suppression of VT in patients with structural heart disease and
ICDs. In the AVID trial, nearly twice as many patients in the ICD arm who ultimately received adjuvant antiarrhythmic therapy were treated with amiodarone compared to either sotalol or mexiletine [17] .
Amiodarone has a low risk of proarrhythmia, despite causing prolongation of the action potential duration and QT interval, probably because it reduces heterogeneity of depolarization. Torsade de pointes occurred in less than 1% in the EMIAT and CAMIAT trials [46, 47] . Extracardiac toxicity, however, is well described, and is related to both a daily and cumulative dose effect of amiodarone. Clinical hypothyroidism occurs in up to 32% of patients, and may require thyroxine supplementation even after drug discontinuation [22] . Hyperthyroidism can also occur, but is less common in the western world where dietary has Class III and beta-blocker effects. Doses less than 120 mg twice daily appear to have a primary beta-blocker effect, with higher doses producing significant Class III activity [22] . A placebo-controlled trial in 302 ICD recipients showed that treatment with racemic sotalol significantly reduced the risk of death or ICD shock (34% incidence with sotalol vs. 54%
with placebo) at 1 year [32] . However, the rate of drug discontinuation in the sotalol arm was 27%.
A similar finding was noted in the OPTIC trial, with nearly a quarter of patients discontinuing sotalol therapy due to drug intolerance [19] . The most common adverse reactions in these trials were related to the beta-blocking effects of the drug; symptomatic bradycardia and torsade de pointes were rare. Of note, in the Survival With
does not have significant beta-blocking effects, was associated with increased mortality and proarrhythmia in patients with post-MI left ventricular dysfunction [33] .
The most significant adverse reaction associated with sotalol is torsade de pointes, seen in 2-3% of patients; especially at risk are women and patients with heart failure or chronic kidney disease (because of its significant renal drug elimination) [48] . For this reason, it is common practice to initiate sotalol therapy in the inpatient setting with continuous ECG monitoring during the loading phase for five doses in patients at higher risk. QT interval prolongation and bradycardia can presage the development of proarrhythmia and may warrant a reduction of the sotalol dose.
Other adverse effects include fatigue, bronchospasm, dyspnea and heart failure.
Unlike amiodarone, these effects are related to the daily dose but not the cumulative dose, making sotalol a more attractive first-line therapy for younger patients or those for whom longer-term treatment is anticipated [22] .
Class I Antiarrhythmic Agents
The Cardiac Arrhythmia Suppression Trial (CAST) compared Class IC agents to placebo in post-MI patients with impaired LVEF (40% or less) for the suppression of ventricular ectopy, and was terminated prematurely due to excess mortality in the antiarrhythmic arm [35] . Both all-cause mortality and arrhythmic death were increased with both encainide and flecainide treatment. As such, Class IC antiarrhythmic agents are no longer recommended therapy for patients with ischemic heart disease or left ventricular dysfunction from any cause. Conversely, the risk of ventricular proarrhythmia with Class IC agents in the absence of structural heart disease is low; however, in patients with atrial arrhythmias, flecainide or propafenone may promote 1:1 atrioventricular nodal conduction with acceleration of the ventricular rate and a wide QRS tachycardia [21] .
Earlier studies that examined Class I agents for secondary VT/VF prevention in post-MI patients showed they were inferior in efficacy to both amiodarone and sotalol [49, 50] . The most commonly used Class I agent in this setting is mexiletine, used in 20% of patients who received adjuvant antiarrhythmic treatment in the ICD arm of the AVID trial [17] . As a Class IB antiarrhythmic agent, it does not seem to carry the increased mortality risk associated with the Class IC drugs, based on observational data with the Class IB drug lidocaine from the Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries (GUSTO-I and GUSTO-IIb) trials [51] .
Quinidine, procainamide, and disopyramide are Class IA antiarrhythmic agents that have intermediate sodium channel blocker activity (compared to Class IC agents) and also prolong action potential duration via potassium channel blockade. They are indicated in the treatment of supraventricular arrhythmias and VT. Unfortunately, use of these agents is limited by the risk of torsade de pointes (seen in 0.5-8%) and the poor tolerability of these agents, including drug-induced lupus with procainamide, anticholinergic effects with disopyramide, and a host of gastrointestinal, dermatologic and neurologic side effects seen with quinidine use [21] .
While the lower efficacy and poor tolerability of the Class I agents has relegated them to third-line therapy for the prevention and treatment of ventricular arrhythmia, there is evidence that combination therapy with a Class I and a Class III agent may be more effective than monotherapy with either agent [43] . [26] . In two earlier randomized trials of dronedarone in patients with atrial fibrillation or flutter, rates of pulmonary, thyroid, and hepatic adverse effects were not significantly greater with dronedarone than with placebo at 1 year follow-up [27] . After its approval in the United States, however, subsequent reports of severe liver toxicity led to a warning by the US Food and Drug Administration, recommending that prescribing physicians follow hepatic function tests routinely [53] .
Although dronedarone has not been studied specifically for the treatment of VT/VF, animal studies have demonstrated antiarrhythmic properties on ventricular myocardium, and subsequent reports in humans have supported its efficacy in select cases [54] [55] [56] . In addition, in ATHENA, patients on dronedarone showed a reduction in arrhythmic death [26] . Decrease (ANDROMEDA) trial, whose results suggest dronedarone may lead to worsening heart failure symptoms and a two-fold increase in mortality in this population [52] . As such, dronedarone is contraindicated in Class IV heart failure patients or in those who have had a recent hospitalization for decompensated heart failure.
The ANDROMEDA study authors recommend that ''dronedarone should not be used in patients with heart failure and reduced left ventricular systolic function.'' A more recent placebocontrolled trial of dronedarone in patients with permanent atrial fibrillation and major vascular risk factors (including CAD and heart failure) was stopped prematurely due to a two-fold excess in cardiovascular mortality [57] . Stroke, hospitalization for heart failure, and arrhythmic deaths were also significantly increased in the dronedarone arm of the Permanent Atrial Fibrillation Outcome Study Using Dronedarone on Top of Standard Therapy (PALLAS) [57] . While some of these adverse findings were unexplained, it was postulated that the negative inotropic 
Ranolazine
Ranolazine is a novel antianginal drug with multiple ion channel blocking antiarrhythmic activity. It is a piperazine derivative with a chemical structure similar to lidocaine, and its most potent ion channel blocking effect is on late sodium current [28, 29, 61, 62] . It is thus considered a Vaughan Williams Class IB agent.
Ranolazine also has effects on the delayed rectifier current (I Kr ) and prolongs action potential duration, with corresponding QT interval prolongation on electrocardiography.
It has been shown in experimental animal models to have antiarrhythmic effects in the ventricle [61, 62] . acute coronary syndrome [29] . It has subsequently been used in the suppression of ectopic ventricular activity [63] and for the reduction in VT burden and prevention of shocks in ICD recipients [64] .
Ranolazine in particular works synergistically with the Class III antiarrhythmic agents, most commonly with amiodarone [65] . This has been demonstrated in animal models to have an antiarrhythmic effect in both the atrium and ventricle. In rabbit hearts treated with both ranolazine and a Class III agent, there was no increase in early after-depolarizations or ventricular proarrhythmia associated with the addition of ranolazine [61] . In addition, in the MERLIN-TIMI 36 trial, despite causing modest QT prolongation, ranolazine use was not associated with an increased risk of SCD compared with placebo [66] . Based on limited but positive clinical experiences with ranolazine, it appears to be beneficial as add-on therapy in patients with recurrent VT events while on a Class III antiarrhythmic agent.
Azilimide
Azimilide is an investigational Class III antiarrhythmic agent that blocks both the rapid (I Kr ) and slow (I Ks ) components of the delayed rectifier cardiac potassium current. It causes prolongation of the atrial and ventricular action potential duration and refractory period [36] . As such, azimilide has demonstrated action against both supraventricular and ventricular arrhythmias. In the Shock Inhibition Evaluation with Azimilide (SHIELD) trial, a randomized controlled trial of 633 secondary prevention ICD recipients, the primary endpoint of all-cause shocks plus symptomatic tachyarrhythmias terminated by antitachycardia pacing was significantly reduced in patients receiving azimilide [36] . In addition, the secondary endpoint of appropriate ICD therapies for VT/VF episodes was reduced by 48% and 62%, with the 75 mg and 125 mg doses of azimilide, respectively.
Based on the concerning results from previous antiarrhythmic drug trials in patients with structural heart disease, such as CAST and SWORD, azimilide was studied prospectively in the Azimilide Postinfarct Survival Evaluation (ALIVE) trial, in which 3,717 patients with recent MI and an ejection fraction between 15% and 35% were randomly assigned to receive azimilide, 100 mg daily, vs. placebo. At 1 year of follow-up, there were no significant differences in all-cause, cardiac, or arrhythmic mortality between the azimilide and placebo groups [67] .
Overall, azimilide was well tolerated in clinical trials. In the SHIELD trial, its discontinuation rate was similar to the placebo arm. Adverse events with azimilide include neutropenia (seen in 1% of patients) and QT prolongation leading to torsade de pointes (seen in up to 1-2% of patients). It is not currently approved for use in North America or Europe.
Celivarone
Celivarone is a noniodinated benzofuran derivative that is in investigational use for its action against atrial and ventricular arrhythmias [37] . Similar to amiodarone and dronedarone, it has Class I, II, III and IV antiarrhythmic activity, but with different relative potencies for the various channels and receptors. Also, its structure and kinetics differ from those of amiodarone and lend itself to an improved side effect profile and reduced potential for drug interactions [68] . It was shown in a small phase 2 clinical study of ICD recipients to trend toward fewer VT and VF episodes at the higher dose of celivarone (300 mg daily), although the 46% relative risk reduction at 6 months was not statistically significant [69] . A larger trial of 486 patients with LVEF of 40% or less and at least one VT/VF episode within a month of enrollment, however, did not find that celivarone was any more effective for the prevention of ICD interventions or sudden death than placebo [68] . In both studies, celivarone was well tolerated and had an acceptable safety profile. Nonetheless, in light of the disappointing clinical data to date, it is not currently approved for use in humans.
Future Antiarrhythmic Targets
Novel targets for the treatment of ventricular arrhythmia continue to be explored, and it is likely that pharmacologic agents directed at some of these targets will enter clinical trials in the next few years. The commonly used antiarrhythmic medications for VT/VF primarily target sodium channels (Class I agents) or potassium channels (Class III agents), but are limited by variable efficacy and the potential for ventricular proarrhythmia. Newer therapeutic approaches to cardiac arrhythmias have focused on the roles of intracellular calcium, gap junctions, sodium-calcium exchange, and adenosine triphosphate (ATP)-sensitive potassium channel blockade, and will be reviewed briefly [37] .
Intracellular Calcium
Altered intracellular calcium handling has been implicated in ventricular arrhythmogenesis in a number of models [6] . was investigated in both a mouse model and in human nonfailing myocardium, and was found to be effective in reducing SR calcium leak [71] . Another recent report showed that inhibition of calcium/calmodulin-dependent kinase (CaMKII) was able to reduce cardiac arrhythmias and SCD in a proarrhythmic mouse model similar to that seen in CPVT [72] .
Gap Junctions
Cell-cell coupling in the heart acts to maintain synchronization of depolarization and repolarization between myocytes, and disruption of this coupling is thought to contribute to arrhythmogenesis. It has been proposed that restoration or enhancement of coupling via gap junctions may be an effective antiarrhythmic target [37] . Connexin 43 is the principal gap junction protein responsible for cell-cell coupling in ventricular myocardium, and its function is impaired during acute ischemia and acidosis [73] . Rotigaptide, an antiarrhythmic peptide that improves conduction across gap junctions, has been shown in experimental animal models to suppress ischemia-induced proarrhythmia [73] . The proposed mechanism of action of rotigaptide is prevention of the dephosphorylation of connexin 43 that accompanies acute metabolic stress. By maintaining gap junction conductance, this peptide in turn both prevents conduction slowing in the cardiomyocytes, and synchronizes the action potentials thereby reducing dispersion of refractoriness [74] .
While the concept of normalizing gap junction conductance with an antiarrhythmic agent is a promising one, there are multiple mechanisms by which gap junction physiology can be impaired in disease states other than by dephosphorylation. The roles of myocyte fibrosis, connexin protein downregulation and trafficking in the remodeling of gap junctions have all been appreciated and may pose challenges to the development of a single pharmacotherapeutic target or agent [73] .
Sodium-Calcium Exchange
The sodium-calcium exchanger (NCX) is the primary pathway for intracellular calcium removal in the cardiomyocyte. It is a cell membrane protein that removes a single calcium ion in exchange for the import of three sodium ions, while operating in the forward mode. Increased expression or activity of NCX has been associated with impaired cardiac contractility and an increased risk of arrhythmias in the setting of heart failure [75] .
NCX also operates in the reverse mode, promoting intracellular calcium loading, during conditions of high cytosolic sodium concentration, or in the setting of digitalis use (which antagonizes the sodium/potassium ATPase). Excessive calcium loading can also be proarrhythmic, as it promotes triggered activity through delayed after-depolarizations [6, 75] .
NCX blockade has been considered to be a potential therapeutic strategy for cardiac arrhythmias, in particular with agents that predominantly inhibit the reverse mode over the forward mode. To date, there has been limited progress in the development of clinically useful agents. Two drugs, KBR-7943 and SEA-0400, have been shown to prevent calcium overload in models of ischemia/reperfusion injury, and appear to reduce after-depolarizations in models of vulnerable cardiac tissue [75] . These findings are promising but await further in vivo confirmation in animal models.
ATP-Sensitive Potassium Channel Blockade
Myocardial ischemia is associated with increases in extracellular potassium, which is believed to contribute to ventricular proarrhythmia. The activation of cardiac cell membrane ATPsensitive potassium channels during myocardial ischemia promotes potassium efflux and reductions in action potential duration; impaired function of the sodium/potassium ATPase may also contribute [76] . In addition, ischemia-induced potassium accumulation is heterogeneous, which leads to dispersion of repolarization and thereby creates a substrate for reentrant arrhythmias. potential duration in models of ischemia, and suppress extrasystoles and VF [76] .
Glibenclamide is a sulfonylurea that also provokes hypoglycemia due to its effects on noncardiac tissue [76] . For ATP-sensitive potassium channel inhibition to become an attractive therapeutic option, cardioselective pharmaceuticals must be developed and tested. Currently, the agents HMR-1883, HMR-1098 and HMR-1402 have been developed and studied in animals, with favorable results on the reduction of ischemic cardiac arrhythmias [77] .
CONCLUSION
In patients with structural heart disease at risk of ventricular arrhythmias, the ICD continues to be the gold standard therapy for the reduction of 
